Analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to post sales of $4.27 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $4.20 billion to $4.32 billion. Teva Pharmaceutical Industries posted sales of $4.70 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.18 billion for the current financial year, with estimates ranging from $17.06 billion to $17.43 billion. For the next year, analysts anticipate that the company will post sales of $17.13 billion, with estimates ranging from $16.73 billion to $17.76 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. Teva Pharmaceutical Industries’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.94 EPS.
A number of equities research analysts recently commented on TEVA shares. Oppenheimer raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Monday, June 3rd. Cantor Fitzgerald raised their target price on Teva Pharmaceutical Industries from $16.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Bank of America lowered Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and decreased their target price for the company from $19.00 to $9.00 in a research report on Thursday, May 30th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, May 10th. Finally, CIBC raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Monday, June 3rd. Five investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average price target of $16.00.
NYSE TEVA traded down $0.01 on Friday, reaching $8.80. The company had a trading volume of 207,421 shares, compared to its average volume of 22,527,716. The stock has a market capitalization of $8.96 billion, a PE ratio of 3.15, a P/E/G ratio of 0.99 and a beta of 1.64. The business has a fifty day moving average price of $10.28. Teva Pharmaceutical Industries has a 52-week low of $7.96 and a 52-week high of $25.96. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66.
In related news, Director Sol J. Barer bought 111,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was acquired at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. boosted its stake in Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after purchasing an additional 767 shares during the period. ARK Investment Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.6% during the 1st quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock valued at $384,000 after acquiring an additional 856 shares during the last quarter. Hancock Whitney Corp boosted its position in shares of Teva Pharmaceutical Industries by 7.8% during the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after acquiring an additional 868 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 61.2% during the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after acquiring an additional 945 shares during the last quarter. Finally, Wedbush Securities Inc. boosted its position in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. Wedbush Securities Inc. now owns 28,385 shares of the company’s stock valued at $445,000 after acquiring an additional 1,015 shares during the last quarter. Institutional investors and hedge funds own 65.08% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.